Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/19/2017 09/20/2017 09/21/2017 09/22/2017 09/25/2017 Date
69.46(c) 70.23(c) 69.5(c) 69.99(c) 69.15(c) Last
1 017 357 870 140 495 380 672 667 751 205 Volume
+0.29% +1.11% -1.04% +0.71% -1.20% Change
More quotes
Financials ($)
Sales 2017 723 M
EBIT 2017 -57,3 M
Net income 2017 -54,1 M
Finance 2017 155 M
Yield 2017 -
Sales 2018 943 M
EBIT 2018 -3,44 M
Net income 2018 -17,3 M
Finance 2018 184 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 8,07x
EV / Sales2018 6,16x
Capitalization 5 986 M
More Financials
Company
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes.Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps.The company was... 
More about the company
Surperformance© ratings of DexCom, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on DEXCOM, INC.
09/19 DEXCOM : Opens Data Platform and Launches Developer Program to Fuel Diabetes App..
09/19 DEXCOM : International Trade Commission Receives Complaint From Dexcom
09/14 FITBIT : and Dexcom to Develop Continuous Glucose Monitoring CGM Experience for ..
09/12 DEXCOM : Submission of Matters to a Vote of Security Holders (form 8-K/A)
09/08 DEXCOM : Announces Upcoming Conference Presentation
08/31 DEXCOM : New Study Shows People with Type 2 Diabetes Benefit from Continuous Glu..
08/21 DEXCOM : New Study Shows People with Type 2 Diabetes Benefit from Continuous Glu..
08/17 EARNINGS REVIEW AND FREE RESEARCH RE : DexCom’s Q2 Top-line Surged 24%; Ou..
08/17 DEXCOM, INC. : Earnings Review and Free Research Report: DexCom’s Q2 Top-line Su..
08/16 INSIDER TRADING ACTIVITY DEXCOM, INC : DXCM) – CEO Sold 6,000 shares of St..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
09/20 ESSILOR INTERNATIONAL : Luxottica, Essilor offer no merger concessions to EU reg..
09/19DJTEVA PHARMACEUTICAL INDUSTRIES : Sells Women's Health Assets -- WSJ
09/18DJTEVA PHARMACEUTICAL INDUSTRIES : Sells Slate of Women's Health Products in Debt-..
09/13 Apple suppliers dent European shares as rally flags
09/12DJMARKET SNAPSHOT : Stock Market Heads To Records As Investors Await Apple Device ..
More sector news : Medical Equipment, Supplies & Distribution - NEC
Latest Tweets
10:41aDexCom $DXCM Earns Daily News Impact Rating of 0.15  
10:31a$DXCM - DexCom #DXCM Earns Daily News Impact Rating of 0.15  
09/25Hey @amazon, there's no good reason Alexa can't tell me my @dexcom blood-suga.. 
09/23$DXCM New SEC Document(s) for DexCom From our Stock News Alerts App 
09/20Somewhat Favorable News Coverage Somewhat Unlikely to Impact DexCom $DXCM Sha.. 
More tweets
Qtime:34
News from SeekingAlpha
09/15 Premarket analyst action - healthcare
09/13 Why The Dexcom Deal Is Big For Fitbit
09/07 Fitbit Enters Another Prudent Partnership
09/07 Fitbit +3.6% on glucose-monitoring partnership
09/01 Lean Long-Term Growth Portfolio - August 2017 Update
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | 4-Traders
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 86,8 $
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer President, Chief Executive Officer & Director
Terrance H. Gregg Executive Chairman
Jeffrey C. Moy Senior Vice President-Operations
Kevin Sun Chief Financial Officer & Vice President
Jacob Leach Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.16.42%5 986
MEDTRONIC PLC11.65%106 024
BAXTER INTERNATIONAL43.23%34 196
C R BARD INC41.83%23 146
ZIMMER BIOMET HOLDINGS INC10.82%23 125
HOYA CORPORATION24.47%21 403